femar25mg - søkeresultat

USA - engelsk - NLM (National Library of Medicine)

femring- estradiol acetate ring

allergan, inc. - estradiol acetate (unii: 5r97f5h93p) (estradiol - unii:4ti98z838e) - estradiol 0.05 mg in 1 d - femring is contraindicated in women with any of the following conditions: - undiagnosed abnormal genital bleeding - known, suspected, or history of breast cancer - known or suspected estrogen-dependent neoplasia - active dvt, pe, or history of these conditions - active arterial thromboembolic disease (for example, stroke and mi), or a history of these conditions - known anaphylactic reaction or angioedema to femring - known liver impairment or disease - known protein c, protein s, or antithrombin deficiency, or other known thrombophilic disorders - known or suspected pregnancy femring should not be used during pregnancy [ see contraindications (4) ] . there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins as an oral contraceptive inadvertently during early pregnancy. femring should not be used during lactation. estrogen administration to nursing women has been shown to decrease the quantity and quality of the breast milk. detectabl

USA - engelsk - NLM (National Library of Medicine)

femring- estradiol acetate ring

physicians total care, inc. - estradiol acetate (unii: 5r97f5h93p) (estradiol - unii:4ti98z838e) - estradiol acetate 0.1 mg in 24 [usp'u] - femring therapy is indicated in the: 1. treatment of moderate to severe vasomotor symptoms due to menopause. 2. treatment of moderate to severe vulvar and vaginal atrophy due to menopause. femring should not be used in women with any of the following conditions: - undiagnosed abnormal genital bleeding. - known, suspected, or history of breast cancer. - known or suspected estrogen-dependent neoplasia. - active deep vein thrombosis, pulmonary embolism or history of these conditions. - active arterial thromboembolic disease (for example, stroke and myocardial infarction) or a history of these conditions. - known liver dysfunction or disease. - known or suspected pregnancy.

USA - engelsk - NLM (National Library of Medicine)

femring- estradiol acetate ring

millicent us, inc. - estradiol acetate (unii: 5r97f5h93p) (estradiol - unii:4ti98z838e) - femring is contraindicated in women with any of the following conditions: - undiagnosed abnormal genital bleeding - known, suspected, or history of breast cancer - known or suspected estrogen-dependent neoplasia - active dvt, pe, or history of these conditions - active arterial thromboembolic disease (for example, stroke and mi), or a history of these conditions - known anaphylactic reaction or angioedema to femring - known liver impairment or disease - known protein c, protein s, or antithrombin deficiency, or other known thrombophilic disorders - known or suspected pregnancy femring should not be used during pregnancy [ see contraindications (4) ] . there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins as an oral contraceptive inadvertently during early pregnancy. femring should not be used during lactation. estrogen administration to nursing women has been shown to decrease the quantity and quality of the breast

Frankrike - fransk - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

femring 50 microgrammes/24 heures, système de diffusion vaginal

galen limited - estradiol - système - 50 microgrammes/24 heures pendant trois mois - de diffusion vaginal composition pour un réservoir de médicament > estradiol : 50 microgrammes/24 heures pendant trois mois . sous forme de : acetate d'estradiol 12,40 mg - estrogènes naturels et hemisynthétiques, non associes.

USA - engelsk - NLM (National Library of Medicine)

femring estradiol acetate

allergan, inc. - estradiol acetate (unii: 5r97f5h93p) (estradiol - unii:4ti98z838e) - estradiol 0.05 mg in 1 d